# INTERVIEW: Evgen Pharma Plc Grossly undervalued say Northland Capital Partners

- Link: https://www.directorstalkinterviews.com/interview-evgen-pharma-plc-grossly-undervalued-say-northland-capital-partners/412721344
- Published: 2017-01-18T07:43:48+00:00
- Author: Giles Arbor

**Evgen Pharma Plc** (LON:EVG) are the topic of conversation with **Northland Capital
Partners head of Research Vadim Alexandre.** Vadim explains the importance of news
that a first patient has been dosed in the Company’s Phase II clinical trial of 
SFX-01 in breast cancer and also talks about Evgen’s prospects over the next few
years.

Evgen Pharma Plc is a clinical stage drug development company whose lead programmes
are in breast cancer and subarachnoid haemorrhage, a type of stroke. It is also 
carrying out preclinical work in multiple sclerosis and has a clinical interest 
in prostate cancer. The Company’s core technology is Sulforadex®, a method for synthesising
and stabilising the naturally occurring compound sulforaphane and novel proprietary
analogues based on sulforaphane. The lead product, SFX-01, is a patented composition
of synthetic sulforaphane and alpha-cyclodextrin. The company commenced operations
in January 2008 and is based in Liverpool, UK, at the Liverpool Science Park. It
joined the AIM market of the London Stock Exchange in October 2015 and trades under
the ticker symbol EVG.

Share on: